caudate-putamen, olfactory tubercle, the lateral septum, and the islands of Calleja. Besides these dopamine-innervated areas the substantia nigra and the ventral tegmental area also showed important receptor densities. Other areas where dopamine D, receptor binding was found were the stratum lacunosum-moleculare of the hippocampus, bands of labeling in the molecular layer of the 9th and 10th lobules of the cerebellum, and several components of the visual system. This distribution presents similarities and differences with previously reported distributions of dopamine D, receptors visualized autoradiographically using 3H-labeled agonists and antagonists.
In view of the high affinity, guanine nucleotide insensitivity, and dopamine D, selectivity of this agonist ligand, it is suggested that dopamine D, receptors exist in different states in different areas. 3H-205-502 appears to be a new and useful tool for the study of dopamine D, receptors.
Many different radiolabeled molecules have been used to study dopamine D, receptors in the mammalian nervous system (Seeman, 198 1; Creese et al., 1983) . The development of these different radioligands has been justified by their lack of pharmacological selectivity for dopamine receptors or their subtypes-D, and D, (Kebabian and Calne, 1979) -and because of the poor technical properties of some of these ligands (i.e., high nonspecific binding or poor chemical stability). The use of radiolabeled dopamine agonists has presented special problems because of the postulated existence of different affinity states of the dopamine receptors (Creese et al., 1984) . 3H-Agonists appear to label predominantly a high-affinity state of the dopamine D, receptor characterized by its high affinity for a third membrane component, one of the guanine-nucleotide binding proteins, a G protein, to form what is called the "ternary complex" (Wreggett and Seeman, 1983) . This complex has been particularly well characterized for dopamine D, receptors (Wreggett and de Lean, 1984) in the pituitary. Some of these ligands have been used for the autoradiographic localization of dopamine receptors after in vivo or in vitro labeling (Palacios and Wamsley, 1984; Kuhar et al., 1986; Palacios and Pazos, 1987) . The most widely used ligand is 3H-spiperone, a ligand with limited receptor selectivity that, besides dopamine D, and 5-HT, receptors, also binds with high affinity to a recognition site without a known pharmacological role, the "spirodecanone binding site" (Palacios et al., 1981; Altar et al., 1985a, b) . More recently, several 3H-and 1251-labeled benzamides have been introduced as selective D, ligands and utilized in receptor localization. These include 'H-sulpiride (Jastrow et al., 1984; Gehlert and Wamsley, 1985) , 1251-sulpride (Martres et al., 1985a, b) , 3H-(-)-D0 710 (Sokoloffet al., 1985) , and 3H-eticlopride (Kiihler et al., 1986) . A novel pyrroloisoquinoline, 3H-R0 22-13 19 (piquindone; Nakajima and Iwata, 1984) has also been used in autoradiographic experiments (Neck et al., 1986) . Finally, autoradiographic localization of dopamine receptors has been investigated with some 3H-labeled agonists, although satisfactory results have been obtained only with 3H-N-n-propylnorapomorphine (Fuxe et al., 1983; Scatton et al., 1984; Dubois and Scatton, 1985; Dubois et al., 1986) , 3H-apomorphine (Bouthenet et al., 1985) being a poor ligand. Recently, 2 new non-catechol dopaminergic agonists with high affinity and selectivity for dopamine D, receptors have been described (Closse et al., 1985; A. Closse, unpublished observations) . These ligands 4a(u, 2, 3, 4, 4a, 5, lO, quinolinyl]sulfamide] and the 6-hydroxy counterpart analog, compound 205-502, are members of a new family of recently synthesized dopamine agonists structurally related to apomorphine and to dopaminomimetic ergolines (Nordmann and Petcher, 1985) . They exceed the receptor specificity of apomorphine, being selective D, agonists, and, as the ergolines, are long-lasting potent agonists. We have now used one of these ligands, 3H-205-502, to visualize dopamine D, receptors in the rat brain.
Materials and Methods
Rats (male Wistar, 180-250 g) were sacrificed by intracardial perfusion with phosphate-buffered saline containing 0.1% formalin, after pentobarbital anesthesia (50 mg/kg). The brains were removed and frozen in liquid nitrogen. Tissue sections, 10 pm thick, were cut using a microtome-cryostat (Leitz 1720, from Leitz, Wetzlar, F.R.G.), mounted onto gelatin-coated microscope slides and stored at -20°C until used.
Slide-mounted rat brain sections were preincubated for 30 min in 'H-205-502 (nM) Figure 1 . After the washing period, tissues were dried with cold air, and autoradiograms were generated by apposing the labeled tissue to 'H-Ultrofilm (LKB, Sweden) as described by Unnerstall et al. (1982) . Exposure period was 60 d at 4°C. Brain gray and white matter standards containing known amounts of a nonvolatile 3H-labeled compound were exposed to the film along with the labeled tissue sections. Films were analyzed using a computerized image-analysis system that provides values of receptor densities expressed in fmol/mg protein. Four to six bilateral measurements were made per nucleus at the level described in each animal, and the mean value was calculated. Values of "specific binding" for each rat were obtained by subtracting the nonspecific binding from the total value. The mean value from equivalent areas in different animals was calculated. Results reported in this study are from at least 2 separate experiments, involving tissues from 3 animals per experiment. Brain nuclei were identified and named using the rat brain atlas of Paxinos and Watson (1982) .
3H-205-502 (107 Ci/mmol) was synthesized and labeled by Dr. R. Voges of the Biopharmaceutical Department, Sandoz Ltd. (Basle, Switzerland). Other chemicals or drugs were of commercial origin or kindly provided by the original manufacturers.
Results
Characteristics of the binding of 3H-20.5-502 to slide-mounted rat brain sections Initially, the incubation conditions described by Closse and collaborators (1985) were used to establish optimal washing parameters for slide-mounted tissues. While the specific binding of 3H-205-502 was stable at 4°C for a relatively long period, nonspecific binding decreased rapidly after 10-l 5 min at 4"C, declining more slowly afterwards. A double 1 min washing protocol was selected for further experiments.
Association of specific 3H-205-502 binding was rapid at room temperature, reaching equilibrium at 60 min incubation. An incubation time of 90 min was selected.
Under the selected conditions, 3H-205-502 binding was found to be saturable and of high affinity (Fig. 1) . The calculated Kd and B,,, values were 0.6 + 0.1 nM and 67.1 f 5.6 fmol/mg protein in rat striatal sections. The specificity and selectivity of 3H-205-502 for dopamine D, receptors were then examined. The binding of 3H-205-502 to rat striatal sections was inhibited with high affinity by several dopamine agonists (Table l) , including dopamine itself, apomorphine, bromocriptine, and the selective dopamine D, agonist 205-501, unlabeled 205-502, and quinpirole (compound LY 17 1555; Tsuruta et al., 1981; Hahn et al., 1983) . In contrast, the selective dopamine D, agonist SKF 38393 (Molloy and Waddington, 1984) showed only low affinity for the sites labeled by 3H-205-502.
The inhibition of 3H-205-502 by dopamine agonists was stereospecific, with (+)iV-propylapomorphine and (+) 3PPP showing affinities in the micromolar range (Table 1) . Dopamine D, receptor antagonists were also potent displacers of 3H-205-502 binding. Again, the displacement was stereoselective, as shown by the differences in affinities exhibited by the d-and l-stereoisomers of sulpit-ide and by (+) and (-) butaclamol. Selective D, antagonists such as YM-0915 l-2 (Grewe et al., 1982; Usuda et al., 1982) were potent blockers, while the selective dopamine D, antagonist SCH 23390 (Hyttel, 1983; Iorio et al., 1983 ) was very weak (Table 1) .
The inhibition of 3H-205-502 binding to rat striatal sections by a number of benzamides was found to depend on the concentration of Na+ ions in the incubation medium (Table 2 ). In the absence of Na+ ions the potencies of sulpiride, remoxipride, The photographs shown here were printed individually to optimize the illustration of receptor distribution, but do not provide information on the quantitative distribution of sites (see Table 2 for these data). Nonspecific binding as defined using 1 PM (+)butaclamol was homogeneously distributed (see Fig. 4B ). Sections were cut approximately in the plane of the atlas of Paxinos and Watson (1982) . and raclopride were 20-100 times lower than in the presence of 120 mM NaCl. The presence of Na+ ions was without influence on the binding of 1 PM 3H-205-502, as was the addition of 100 PM GTP to the incubation medium.
The regional sensitivity of 3H-205-502 binding to drugs was examined by autoradiography using single concentrations of displacers and sagittal and coronal brain sections. The binding of 3H-205-502 was equally sensitive to 1 PM butaclamol in all the brain regions and insensitive to coincubations with 1 PM SCH 23390,l PM SKF 38393,l PM clonidine, 1 PM propranolol, and 1 mM GppNHp.
Regional distribution of ;'H-205-502 binding sites (DA-D, receptors) in the rat brain
The distribution of dopamine D, receptors as labeled by 3H-205-502 in the. rat brain is illustrated in Figures 2-4 . The densities (expressed in fmol/mg protein) of 3H-205-502 binding sites determined microdensitometrically are given in Table 3 . The highest densities of dopamine D, sites labeled by 3H-205-502 were found in areas of the basal ganglia and associated structures. The caudate-putamen contained the highest densities. The distribution of binding sites in this region was, however, very heterogeneous, with the ventrolateral and lateral areas showing the highest densities and the medial levels the lowest. The islands of Calleja were also very rich in receptor sites. The nucleus accumbens and olfactory tubercles also showed high densities, while the globus pallidus was an area poor in D, sites. In the midbrain, the substantia nigra compacta and the ventral tegmental area showed high densities of 3H-205-502 binding sites, while the substantia n&a reticulata showed only low levels of binding. In addition, the superficial gray layer of the superior colliculus also exhibited high-density binding. Interestingly, another component of the visual pathway, the olivary pretectal nucleus (OPT) was also labeled (Fig. 2H ). Significant numbers of dopamine D, receptors were labeled by 3H-205-502 in other brain areas, outside the nigrostriatal and mesolimbic pathways. These included the glomerular layer of the olfactory bulb (Figs.  2A,3, and 4) , the lateral septum, and the lateral mammillary bodies. In the hippocampal formation, a band of high-density binding was found that corresponded to the stratum lacunosom moleculare of the dorsal hippocampus, densities of 'H-205-502 sites being lower in the rest of the hippocampus and dentate gyrus. The entorhinal cortex showed a laminar distribution of sites, with the external laminae being richer than the deeper ones (Fig. 3B ).
Low densities of receptors were seen in many other brain areas, including the cortex (particularly the deepest laminae of the frontal cortex), stria terminalis, hypothalamus, forebrain, periventricular gray, inferior colliculi, the nucleus interpeduncularis in the midbrain, and the nucleus tractus solitarius in the medulla oblongata.
The cerebellum contained only very low, uniformly distributed numbers of binding sites with the remarkable exception of the molecular layer of the 9th and 10th lobules, where highdensity bands of 3H-205-502 binding sites were visualized. 
Discussion
The main findings of these investigations could be summarized as follows: (1) The non-catechol dopamine agonist 3H-205-502 labels sites with the characteristics of dopamine D, receptors in mounted tissue sections of rat brain. (2) The autoradiographic distribution of these sites reveals similarities and differences with previously reported distributions of dopamine D, sites studied with other ligands.
Evidence for the binding of 3H-205-502 to D, sites is provided by the selective blockade of the binding of this ligand by dopamine D, compounds such as quinpirole (LY 17 15 55: Tsuruta et al., 1981; Hahn et al., 1983 ), 205-501 (Closse et al., 1985 , sulpiride, YM-09151-2, and other benzamides (Grewe et al., 1982; Usuda et al., 1982) but not by D, compounds such as SKF 38393 and SCH 23390 (Hyttel, 1983; Iorio et al., 1983; Molloy and Waddington, 1984) . The binding of 3H-205-502 was stereospecifically blocked by the isomers of butaclamol and sulpiride. In addition, the inhibition of 3H-205-502 by the benzamide neuroleptics was found to be dependent on the presence of Na+ ions, while the presence or absence of Na+ ions was without influence on the binding of the ligand (Stefanini et al., 1980) . Under our incubation conditions the addition of the guanylnucleotide GTP to the incubation medium was also without significant effect on 3H-205-502 binding. These characteristics are similar to data obtained in bovine caudate membrane preparations with this ligand (A. Closse, unpublished observations) and with 'H-205-50 1, a closely related molecule (Closse et al., 1985) , contrasting with results obtained with other 3H-labeled dopamine analogs, such as 3H-N-n-propylnorapomorphine (Creese et al., 1984) . Dopamine D, receptors have been visualized autoradiographically using several ligands differing in their receptor selectivity, agonist or antagonist character, and technical characteristics (see introduction). The results obtained with most of these ligands are in close agreement regarding the labeling of a number of brain areas where dopaminergic innervation is well documented. These areas include first the striatonigral pathway, where the highest densities of dopamine D, receptors in the rat brain have been localized in the nucleus caudate putamen, while little binding has been seen in the globus pallidus (Palacios et al., 198 1; Jastrow et al., 1984; Altar et al., 1985a, b; Dubois and Scatton, 1985; Gehlert and Wamsley, 1985; Joyce et al., 1985; Martres et al., 1985a, b; Sokoloff et al., 1985; Kiihler et al., 1986; Neck et al., 1986) . Furthermore, a heterogeneous distribution of sites has been observed, with highest densities being localized with both 3H-spiperone and 3H-N-n-propylnorapomorphine in the ventral lateral aspects of the nucleus and lower densities in the medial and lateral dorsal striatum (Dubois and Scatton, 1985; Joyce et al., 1985) . High densities of D, receptors are also labeled by the different ligands used until now in the nucleus accumbens and olfactory tubercle (references as above).
Although not always reported, it appears from the published autoradiograms as if the islands of Calleja were also highly labeled by all the dopamine D, radioligands used in autoradiography. Relatively high to moderate densities of dopamine D, receptors have also been localized to dopaminergic cell bodies in the substantia nigra pars compacta and ventral tegmental area, while lower concentrations were generally observed in the substantia nigra zona reticulata. High densities of dopamine D, receptors have also been visualized in all previous studies with different ligands in the glomerular layer of the olfactory bulb (Palacios et al., 198 1) . These studies also agree on the presence of moderate concentrations of D, sites in areas such as the superficial gray layer of the superior colliculi, the central gray, the lateral mammillary nucleus, and the lateral septum. The distribution of 3H-205-502 binding sites in these brain areas reported here is also in good qualitative agreement with the results obtained with other D, dopaminergic ligands. However, outside of these well-characterized dopaminergic areas, the diverse autoradiographic studies present many discrepancies regarding the labeling of D, receptors. Thus, Martres and colleagues (1985a, b) have reported a widespread distribution of dopamine D, receptors in the rat brain visualized by the use of 1251-iodosulpride, a ligand with 20-100 times higher specific activity than that of previously used probes. Using lzsIiodosulpride, sites with the properties of dopamine D, receptors were visualized in the neocortex, the cerebellar cortex, and the stratum lacunosum moleculare of the hippocampus. These sites were not labeled in previous studies, in particular, in those using 3H-spiperone. The reasons for this could be related to the fact that the densities in neocortex and cerebellum are on the order of l-5% of those of the striatum and to the presence of high densities of the so-called spirodecanone binding site in the hippocampus. Gehlert and Wamsley (1985) , using another benzamide ligand, 3H-sulpiride, reported the presence of D, receptors in the stratum lacunosum moleculare and in the cerebellum, although in this structure the binding was limited to the nodulus. However, other investigators, using 3H-sulpiride (Jastrow et al., 1984) , other 3H-labeled benzamide ligands such as 3H-(-)-D0 7 10 (Sokoloff et al., 1985) or 3H-eticlopride (KBhler et al., 1986) or the rigid pyrroloisoquinoline 3H-piquindone (Neck et al., 1986) have failed to visualize any binding in these regions. Dubois et al. (1986) , who used the agonist ligand 3H-N-n-propylnorapomorphine, failed to localize D, sites in neocortical areas (first reported after in vivo labeling with 3H-spiperone by Klemm et al., 1979) or the cerebellar cortex, although a low level ofbinding was seen in the hippocampus.
)H-205-502 clearly labels sites with the properties of dopamine D, receptors in areas where 1251-iodosulpride and, in some cases, 3H-sulpiride have also shown the presence of these sites, namely, the neocortex, the stratum lacunosum moleculare of the hippocampus, the entorhinal cortex, and the cerebellum (Gehlert and Wamsley, 1985; Mar&es et al., 1985a, b) . However, clear differences exist between the distribution of 1251-iodosu1-pride sites and those labeled in the neocortex and cerebellum by 3H-205-502. Thus, the sites labeled by the non-catechol agonist were localized in the neocortex to the deep (V and VI) laminae. In the cerebellum they were organized in bandlike structures in the molecular layers of lobules 9 and 10 in the cerebellum, probably corresponding to the organization of the climbing fibers (Beyerl et al., 1982) . In contrast, those labeled by the benzamide were seen in laminae I-III and V of the neocortex and in the molecular layer of the entire cerebellum (Martres et al., 1985b) .
In addition to the above-mentioned differences in the distribution of putative dopamine D, receptors visualized with different ligands, it should also be mentioned that the entorhinal cortex and some amygdaloid nuclei appear to be differentially labeled by these ligands. Thus, binding to the entorhinal cortex has been seen with 3H-spiperone (Altar et al., 1985a, b; Palacios and Pazos, 1987) , 3H-sulpiride (Gehlert and Wamsley, 1985) 1*51-iodosulpride (Martres et al., 1985a, b) , 3H-eticlopride (Kohler et al., 1986 ) and 3H-205-502 (this study) but not with 3H-N-n-propylnorapomorphine (Dubois et al., 1986) or 3H-sulpiride (Jastrow et al., 1984) and is not mentioned in the studies with 3H-( -)-DO 7 10 (Sokoloff et al., 1985) and 3H-piquindone (Neck et al., 1986) . The central amygdaloid nucleus is highly labeled by 3H-spiperone but not so strongly by other ligands, including 3H-sulpiride (Gehlert and Wamsley, 1985) , L*51-su1-pride (Martres et al., 1985a), or 3H-205-502 (this study) .
An additional complication encountered when comparing the results obtained in the autoradiographic studies on dopamine D, receptors in the rat brain is the marked difference in the number of sites and in the relative proportions of these sites labeled by the different ligands. In part, these differences are due to differing degrees of receptor occupancy. Thus, values of about 2700 and 4600 fmol/mg protein 3H-spiperone binding in the lateral striatum are reported by Altar et al. (1985a, b) , while in the same region we found, with the same ligand, densities of about 1500 fmol/mg protein. Results with labeled benzamides vary from 17.3 fmol/mg tissue (Gehlert and Wamsley, 1985) to 300 fmol/mg protein (Jastrow et al., 1984) for 3H-sulpiride, while 'Y-iodosulpride (Martres et al., 1985b) shows a maximal capacity of 33.7 fmol/mg protein in striatal membrane preparations. More interestingly, differences are also found in the relative labeling of different regions by the diverse ligands, where differences in occupancy should not have an influence. Thus, ratios lateral striatum/substantia nigra compacta of 3.8 Pazos, 1987), 8.3 (Jastrow et al., 1984) , 6.2 (Gehlert and Wamsley, 1985) 9.2 (Dubois et al., 1986 ), 8.4 (Neck et al., 1986 , and 1.5 (present results) have been reported.
Since all these ligands appear to label dopamine D, receptors, as defined by the affinity and selectivity of reputed selective agonists and antagonists, the differential labeling of subclasses of the D, receptor or of different affinity states or forms of the same receptor have to be postulated in order to reconcile the diverse results, unless unknown technical factors determine the differences in distribution and density of sites labeled by the different ligands. In fact, differences exist in, for example, the dependency on the presence of Na+ ions for the binding of some antagonists and the sensitivity to guanylnucleotides of some agonists and antagonists. Thus, while the binding of 3H-sulpiride and )H-piquindone are Na+ sensitive (Stefanini et al., 1980; Nakajima and Iwata, 1984) , 3H-spiperone binding is not. On the other hand, a decrease in 3H-N-n-propylnorapomorphine binding and an increase in l*SI-iodosulpride binding have been found when GTP is added to the incubation medium, whereas in our studies 3H-205-502 was found to be insensitive to the nucleotide.
In conclusion, the use of 3H-205-502 has revealed the presence of dopamine D, receptors in significant densities in areas where other dopaminergic ligands did not exhibit relevant binding, as well as in other well-characterized brain areas for which agreement already exists about the presence of dopamine D, receptors. Further studies are, however, still necessary to clarify the exact characteristics of some of these binding sites, the existence of different forms or states of the receptor in different brain areas, and the functional significance, if any, of these sites.
